In addition, considering the major role excess NETs play in COVID-19 severity, targeting NET formation by inhibiting molecules critical for their production (e.g., neutrophil elastase (NE), PAD4, and gasdermin D)70–72 is a promising therapeutic choice for reducing clinical severity in COVID-19. The gene discussed is GSDMD; the disease is COVID-19.